{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T13:07:57Z","timestamp":1765112877312,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jaad.2019.07.021","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T12:31:40Z","timestamp":1563193900000},"page":"489-491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pralatrexate for refractory or recurrent subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic syndrome"],"prefix":"10.1016","volume":"82","author":[{"given":"Olivia","family":"Ware","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica S.","family":"Tarabadkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Shustov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michi M.","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2019.07.021_bib1","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group study of 83 cases","volume":"111","author":"Willemze","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2019.07.021_bib2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clml.2011.06.016","article-title":"Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations","volume":"12","author":"Mehta","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"10.1016\/j.jaad.2019.07.021_bib3","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","article-title":"Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"119","author":"Horwitz","year":"2012","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.jaad.2019.07.021_bib4","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1158\/1078-0432.CCR-16-2064","article-title":"Results from a phase I\/II Open-label, dose-finding study of pralatrexate and oral bexarotene in patients with relapsed\/refractory cutaneous T-cell lymphoma","volume":"23","author":"Duvic","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.jaad.2019.07.021_bib5","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T- cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219323795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219323795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:52:44Z","timestamp":1759272764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219323795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0190962219323795"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.07.021","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pralatrexate for refractory or recurrent subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}